Guided Therapeutics (GTHP) Cash & Equivalents Growth (5y) (2015 - 2026)
Guided Therapeutics (GTHP) Cash & Equivalents Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.03% |
| Dec 31, 2025 | -19.12% |
| Sep 30, 2025 | -31.60% |
| Jun 30, 2025 | -24.68% |
| Mar 31, 2025 | 40.51% |
| Dec 31, 2024 | -15.47% |
| Mar 31, 2024 | 136.61% |
| Sep 30, 2023 | 59.87% |
| Jun 30, 2023 | 101.38% |
| Mar 31, 2023 | 89.09% |
| Dec 31, 2022 | 370.80% |
| Sep 30, 2022 | 105.27% |
| Jun 30, 2022 | 123.49% |
| Mar 31, 2022 | 273.31% |
| Dec 31, 2021 | 114.99% |
| Sep 30, 2021 | 166.83% |
| Jun 30, 2021 | 111.09% |
| Mar 31, 2021 | 86.01% |
| Dec 31, 2020 | 39.06% |
| Sep 30, 2020 | 27.56% |